Reshma Parab, MD
Endocrinology, Diabetes & Metabolism · Fredericksburg, VANPI 1073549325
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,861 of the $5,531 with a category attached, or 69.8%. 34 manufacturers reported payments, led by Medtronic at 40.8% of the total. Reporting peaked in 2022 at $2,642 and has fallen 70.4% since, to $782 in 2025.
Across 186 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Lilly USA, LLC$480
- Novo Nordisk$334
- IBSA Pharma Inc.$310
- Boehringer Ingelheim$300
- Abbott$254
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,62229%
- Food & beverage$3,86170%
- Education$80%
- Other$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 24 | $2,259 |
| Lilly USA, LLC | 26 | $480 |
| Novo Nordisk | 13 | $334 |
| IBSA Pharma Inc. | 14 | $310 |
| Boehringer Ingelheim | 21 | $300 |
| Abbott | 12 | $254 |
| Xeris Pharmaceuticals, Inc. | 9 | $209 |
| Insulet Corporation | 8 | $160 |
| Sanofi-aventis U.S. LLC | 8 | $156 |
| Lifescan, Inc. | 6 | $155 |
| Amgen(2 entities) | 6 | $126 |
| Amneal Pharmaceuticals LLC | 7 | $123 |
| Tandem Diabetes Care, Inc. | 3 | $60 |
| Averitas Pharma Inc. | 3 | $59 |
| AbbVie | 3 | $55 |
| Lundbeck LLC | 2 | $53 |
| Corcept Therapeutics | 2 | $45 |
| Dexcom, Inc. | 2 | $43 |
| AstraZeneca | 2 | $42 |
| SK Life Science, Inc. | 1 | $31 |
| Intuity Medical Inc | 1 | $31 |
| Johnson & Johnson | 1 | $30 |
| Novartis | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $21 |
| BD | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Valeritas, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $17 |
| Bayer | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,444
- Wegovy$125
How this compares
$5,531 in reported general payments places this provider in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 230 | $491,553 |
| TrulicityDulaglutide | 147 | $278,297 |
| JardianceEmpagliflozin | 100 | $133,391 |
| MounjaroTirzepatide | 85 | $129,551 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $77,742 |
| JanuviaSitagliptin Phosphate | 54 | $69,077 |
| Humulin R U-500Insulin Regular, Human | 14 | $55,198 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 54 | $43,173 |
| FarxigaDapagliflozin Propanediol | 42 | $37,914 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $36,908 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $35,261 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 177 | $34,281 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $31,756 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $31,061 |
| Novolog FlexpenInsulin Aspart | 85 | $25,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $334 | $505,524290 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N, Insulin Lispro | $480 | $422,541304 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi | $300 | $195,362169 claims |
| MerckJanuvia, Janumet | $11 | $84,79366 claims |
| AstraZenecaFarxiga | $42 | $37,91442 claims |
| AbbVieSynthroid, Armour Thyroid | $55 | $13,129139 claims |
| Sanofi-aventis U.S. LLCLantus | $156 | $11,53559 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $123 | $7,162537 claims |
| IBSA Pharma Inc.Tirosint | $310 | $3,26411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Fredericksburg
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.